The cost of cancer care: how far would you go for a trial?
Clinical trials
Distance
Expense
Oncology
Journal
Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
24
11
2021
accepted:
30
12
2021
pubmed:
18
1
2022
medline:
22
11
2022
entrez:
17
1
2022
Statut:
ppublish
Résumé
Clinical trials are often considered the gold standard in cancer care. However, patients face barriers in trial participation including distances to cancer centres and personal costs including changing employment status, cost of medications, inpatient admissions, and parking tariffs. Our aim was to compare the distances patients travelled for clinical trials compared to those receiving standard systemic anticancer therapy (SACT). We also investigated the additional costs associated with this. This was a retrospective review of electronic patient medical records. The distance from the patients' home address to Beaumont was calculated as a one-way journey in kilometres. Patients attending for clinical trials were compared to those receiving standard of care SACT. A total of 271 patients receiving standard SACT over a 5-day period and 111 patients enrolled on 24 clinical trials were included. The median one-way distance travelled by patients enrolled in clinical trials was 41.4 km, compared to 14 km in those patients' receiving standard of care SACT. The median estimated cost was €13 vs €4.20 for those enrolled on clinical trials compared to those receiving standard of care treatment, respectively. Patients enrolled on clinical trials often travel more than twice as far to receive their anti-cancer treatment compared to those receiving standard of care SACT and incur an increased cost of travel expenses.
Sections du résumé
BACKGROUND
BACKGROUND
Clinical trials are often considered the gold standard in cancer care. However, patients face barriers in trial participation including distances to cancer centres and personal costs including changing employment status, cost of medications, inpatient admissions, and parking tariffs.
AIM
OBJECTIVE
Our aim was to compare the distances patients travelled for clinical trials compared to those receiving standard systemic anticancer therapy (SACT). We also investigated the additional costs associated with this.
METHODS
METHODS
This was a retrospective review of electronic patient medical records. The distance from the patients' home address to Beaumont was calculated as a one-way journey in kilometres. Patients attending for clinical trials were compared to those receiving standard of care SACT.
RESULTS
RESULTS
A total of 271 patients receiving standard SACT over a 5-day period and 111 patients enrolled on 24 clinical trials were included. The median one-way distance travelled by patients enrolled in clinical trials was 41.4 km, compared to 14 km in those patients' receiving standard of care SACT. The median estimated cost was €13 vs €4.20 for those enrolled on clinical trials compared to those receiving standard of care treatment, respectively.
CONCLUSION
CONCLUSIONS
Patients enrolled on clinical trials often travel more than twice as far to receive their anti-cancer treatment compared to those receiving standard of care SACT and incur an increased cost of travel expenses.
Identifiants
pubmed: 35038110
doi: 10.1007/s11845-021-02915-6
pii: 10.1007/s11845-021-02915-6
pmc: PMC8761872
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2487-2491Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Borno HT, Zhang L, Siegel A et al (2018) At what cost to clinical trial enrollment? A retrospective study of patient travel burden in cancer clinical trials. Oncologist 23(10):1242–1249
doi: 10.1634/theoncologist.2017-0628
pubmed: 29700209
pmcid: 6263122
National Cancer Registry (2019) Cancer care and survival in relation to centralisation of Irish cancer services: an analysis of National Cancer Registry data 1994–2015 [Internet]. National Cancer Registry, Ireland. [cited 10 Oct 2021]. Available from: https://www.ncri.ie/sites/ncri/files/pubs/CancerCentralisation_NCRI_Jan2019_fullreport_29012019_final.pdf
Ambroggi M, Biasini C, Del Giovane C et al (2015) Distance as a barrier to cancer diagnosis and treatment: review of the literature. Oncologist 20(12):1378–1385
doi: 10.1634/theoncologist.2015-0110
pubmed: 26512045
pmcid: 4679078
Thomas AA, Gallagher P, O’Céilleachair A et al (2015) Distance from treating hospital and colorectal cancer survivors’ quality of life: a gendered analysis. Support Care Cancer 23(3):741–751
doi: 10.1007/s00520-014-2407-9
pubmed: 25179691
Lee B, Goktepe O, Hay K et al (2014) Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British Columbia. Oncologist [Internet]. [cited 9 Mar 2021];19(3). Available from: https://pubmed.ncbi.nlm.nih.gov/24569946/
Collins DC, Coghlan M, Hennessy BT et al (2017) The impact of outpatient systemic anti-cancer treatment on patient costs and work practices. Ir J Med Sci [Internet]. [cited 9 Mar 2021];186(1). Available from: https://pubmed.ncbi.nlm.nih.gov/27498210/
Fogel DB (2018) Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun 11:156–164
doi: 10.1016/j.conctc.2018.08.001
pubmed: 30112460
pmcid: 6092479
Sharrocks K, Spicer J, Camidge DR, Papa S (2014) The impact of socioeconomic status on access to cancer clinical trials. Br J Cancer 111(9):1684–1687
doi: 10.1038/bjc.2014.108
pubmed: 25093493
pmcid: 4453719
Sateren WB, Trimble EL, Abrams J et al (2002) How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 20(8):2109–2117
doi: 10.1200/JCO.2002.08.056
pubmed: 11956272
Byrne J (2021) Average price paid for new car now over €33,000 - Cartell Car Check [Internet]. [cited 25 Oct 2021]. Available from: https://www.cartell.ie/2021/01/average-price-paid-for-new-car-now-over-e33000/
Route planner: route calculation, detailed journey cost - ViaMichelin [Internet]. [cited 25 Oct 2021]. Available from: https://www.viamichelin.ie/web/Routes
Paul C, Boyes A, Hall A et al (2016) The impact of cancer diagnosis and treatment on employment, income, treatment decisions and financial assistance and their relationship to socioeconomic and disease factors. Support Care Cancer 24(11):4739–4746
doi: 10.1007/s00520-016-3323-y
pubmed: 27364149
Irish Cancer Society [Internet] The SAGE Encyclopedia of Cancer and Society. Available from: https://doi.org/10.4135/9781483345758.n297
Wagner L, Lacey MD (2004) The hidden costs of cancer care: an overview with implications and referral resources for oncology nurses. Clin J Oncol Nurs 8(3):279–287
doi: 10.1188/04.CJON.279-287
pubmed: 15208822
Desai A, Gyawali B (2020) Financial toxicity of cancer treatment: moving the discussion from acknowledgement of the problem to identifying solutions. E Clinical Medicine 20:100269
Zajacova A, Dowd JB, Schoeni RF, Wallace RB (2015) Employment and income losses among cancer survivors: estimates from a national longitudinal survey of American families. Cancer 121(24):4425–4432
doi: 10.1002/cncr.29510
pubmed: 26501494
Carrera PM, Kantarjian HM, Blinder VS (2018) The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 68(2):153–165
doi: 10.3322/caac.21443
pubmed: 29338071
pmcid: 6652174
Kobayashi K, Morita S, Shimonagayoshi M et al (2008) Effects of socioeconomic factors and cancer survivors’ worries on their quality of life (QOL) in Japan. Psychooncology 17(6):606–611
doi: 10.1002/pon.1278
pubmed: 17972358
Earle CC, Venditti LN, Neumann PJ et al (2000) Who gets chemotherapy for metastatic lung cancer? Chest 117(5):1239–1246
doi: 10.1378/chest.117.5.1239
pubmed: 10807806
Mirza A-S, Pabbathi S, Lu Y et al (2018) Comorbidities, risk, and socioeconomic factors of uninsured cancer survivors. Medicine 97(47):e13121
Kearns C, Feighery R, Mc Caffrey J et al (2020) Understanding and attitudes toward cancer clinical trials among patients with a cancer diagnosis: national study through Cancer Trials Ireland. Cancers [Internet] 16;12(7) Available from: https://doi.org/10.3390/cancers12071921
Neuner JM, Kong A, Blaes A et al (2019) The association of socioeconomic status with receipt of neoadjuvant chemotherapy. Breast Cancer Res Treat 173(1):179–188
doi: 10.1007/s10549-018-4954-0
pubmed: 30232683
Lara PN Jr, Paterniti DA, Chiechi C et al (2005) Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol 23(36):9282–9289
doi: 10.1200/JCO.2005.02.6245
pubmed: 16361626
Morris PG, Kelly R, Horgan A et al (2007) Patterns of participation of patients in cancer clinical trials in Ireland. Ir J Med Sci 176(3):153–156
doi: 10.1007/s11845-007-0058-2
pubmed: 17619093
Dublin City Council local economic and community plan [Internet]. [cited 12 Dec 2021]. Available from: https://consultation.dublincity.ie/admin/lecp/supporting_documents/Dublin%20City%20Socio%20Economic%20Profile.pdf
Mandelblatt JS, Yabroff KR, Kerner JF (1999) Equitable access to cancer services: a review of barriers to quality care. Cancer 86(11):2378–2390
doi: 10.1002/(SICI)1097-0142(19991201)86:11<2378::AID-CNCR28>3.0.CO;2-L
pubmed: 10590381
Kronenfeld JJ (2011) Access to care and factors that impact access, patients as partners in care and changing roles of health providers. Emerald Group Publishing 331
Hendren S, Chin N, Fisher S et al (2011) Patients’ barriers to receipt of cancer care, and factors associated with needing more assistance from a patient navigator. J Natl Med Assoc 103(8):701–710
pubmed: 22046847
Wallington SF, Dash C, Sheppard VB et al (2016) Enrolling minority and underserved populations in cancer clinical research. Am J Prev Med 50(1):111–117
doi: 10.1016/j.amepre.2015.07.036
pubmed: 26470805
Lara PN Jr, Higdon R, Lim N et al (2001) Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 19(6):1728–1733
doi: 10.1200/JCO.2001.19.6.1728
pubmed: 11251003
Richards M, Anderson M, Carter P et al (2020) The impact of the COVID-19 pandemic on cancer care. Nature Cancer 1(6):565–567
doi: 10.1038/s43018-020-0074-y
pubmed: 35121972
pmcid: 7238956
Nabhan C, Choueiri TK, Mato AR (2020) Rethinking clinical trials reform during the COVID-19 pandemic. JAMA Oncol 6(9):1327–1329
doi: 10.1001/jamaoncol.2020.3142
pubmed: 32761101
Doroshow JH, Prindiville S, McCaskill-Stevens W et al (2021) COVID-19, social justice, and clinical cancer research. J Natl Cancer Inst 113(10):1281–1284
doi: 10.1093/jnci/djaa162
pubmed: 33057660
Unger JM, Blanke CD, LeBlanc M, Hershman DL (2020) Association of the coronavirus disease 2019 (COVID-19) outbreak with enrollment in cancer clinical trials. JAMA Netw Open 3(6):e2010651
Waterhouse DM, Harvey RD, Hurley P et al (2020) Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology Survey. JCO Oncology Practice [Internet]. [cited 12 Dec 2021]. Available from: https://doi.org/10.1200/OP.20.00275
Robinson M (2021) Average new car price in 2020 hits €33,287 [Internet]. [cited 10 Mar 2021]. Available from: https://www.completecar.ie/car-news/article/10674/Average-new-car-price-in-2020-hits-33287#:~:text=Cartell.ie%2C%20the%20vehicle%20history,exceeded%20the%20%E2%82%AC30%2C000%20mark